Subscribe

SenzaGen AB (SENZA.ST)

SEK5.30 -0.10 (-1.85%)
SE STO Healthcare Medical - Diagnostics & Research
Address Building 401 223 81
Lund, SE
CEO Peter Nahlstedt
Website senzagen.com
IPO 2017-09-21
ISIN SE0010219626

Explore sections of this company profile

Description

SenzaGen AB specializes in pioneering, conducting, and commercializing animal-free methods to evaluate the allergic potential of various substances. Their product portfolio encompasses several in vitro tests: GARDskin identifies potential chemical skin sensitizers; GARDpotency, an enhancement to GARDskin, categorizes their strength; GARDskin Dose-response delivers precise quantitative assessment of skin sensitizing potency; and GARDair detects chemical respiratory sensitizers. They also offer GARDskin medical device for assessing skin sensitization caused by medical equipment and solid materials. Furthermore, the company provides services for irritation and corrosion analysis. SenzaGen distributes its solutions through a network of licensed partners and distributors. The firm also collaborates with the Research Institute for Fragrance Materials to develop novel photosensitization tests. Founded in 2010, the company's headquarters are located in Lund, Sweden.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
SEK5.30 -0.10 (-1.85%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
18.0K
Beta
0.53
Float Shares
24.40M
Free Float %
75.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.11% -0.74% -1.48% -5.99% -16.82% -11.00% +5.12% -52.53% -63.30% -87.36% -87.36%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
5.30
Ratings Trend (MoM)
Rating 2025-08 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
0.94
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Diagnostics & Research: +7.9%
    +0.5% Q1'26: +9.5% (vs Q1'25)
  • ✗
    EPS growth Medical - Diagnostics & Research: +30.8%
    +40.0% ★ Q1'26: +56.6% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%
    -23.7% Q1'26: -24.3% (vs Q1'25)
  • ✗
    EBIT margin Medical - Diagnostics & Research: +9.6%
    -19.8% Q1'26: -14.8% (vs Q1'25)
  • ✗
    ROIC Medical - Diagnostics & Research: +5.2%
    -14.4% Q1'26: -11.5% (vs Q1'25)
  • ✗
    Share dilution Medical - Diagnostics & Research: 0.0%
    +8.1% Q1'26: +6.8% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×
    -3.93× Q1'26: -3.68× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.54) × ERP
WACC = 85% × Ke + 15% × Kd (4.4%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 5.30
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
41.77M
est: 44.00M (-5.1%)
49.87M
est: 55.29M (-9.8%)
57.70M
est: 62.15M (-7.2%)
57.97M
est: 68.30M (-15.1%)
93.50M
93.50M – 93.50M
+36.9% YoY
136.30M
136.30M – 136.30M
+45.8% YoY
184.00M
184.00M – 184.00M
+35.0% YoY
EBITDA
-15.50M
est: -24.67M (+37.2%)
-13.75M
est: -21.34M (+35.5%)
-9.06M
est: -23.99M (+62.2%)
-7.30M
est: -26.36M (+72.3%)
-36.09M
-36.09M – -36.09M
-36.9% YoY
-52.60M
-52.60M – -52.60M
-45.8% YoY
-71.01M
-71.01M – -71.01M
-35.0% YoY
EBIT
-24.92M
est: -29.45M (+15.4%)
-21.94M
est: -28.14M (+22.0%)
-17.88M
est: -31.63M (+43.5%)
-11.50M
est: -34.76M (+66.9%)
-47.59M
-47.59M – -47.59M
-36.9% YoY
-69.37M
-69.37M – -69.37M
-45.8% YoY
-93.65M
-93.65M – -93.65M
-35.0% YoY
Net Income
-24.91M
est: -27.29M (+8.7%)
-22.10M
est: -24.68M (+10.5%)
-17.85M
est: -14.46M (-23.5%)
-11.59M
est: -5.02M (-131.0%)
10.62M
10.62M – 10.62M
+311.8% YoY
22.13M
22.13M – 22.13M
+108.3% YoY
44.26M
44.26M – 44.26M
+100.0% YoY
SGA
39.03M
est: 76.36M (-48.9%)
45.93M
est: 64.04M (-28.3%)
44.31M
est: 71.99M (-38.4%)
45.41M
est: 79.11M (-42.6%)
108.30M
108.30M – 108.30M
+36.9% YoY
157.88M
157.88M – 157.88M
+45.8% YoY
213.13M
213.13M – 213.13M
+35.0% YoY
EPS
-1.03
est: -1.00 (-3.0%)
-0.91
est: -0.84 (-8.8%)
-0.65
est: -0.49 (-32.7%)
-0.39
est: -0.17 (-129.4%)
0.36
0.36 – 0.36
+311.8% YoY
0.75
0.75 – 0.75
+108.3% YoY
1.50
1.50 – 1.50
+100.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-28 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-27 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-26 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-25 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-22 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-21 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-20 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-19 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-18 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-15 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-13 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-12 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-11 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-08 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-07 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-06 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-05 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-04 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-30 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-29 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-28 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-27 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-24 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-23 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-22 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-21 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-20 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-17 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-16 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-11.15M
OE per share TTM
-0.37
Owner's Yield
-6.63%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
13.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-338.2K
Shares Outstanding
32.51M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Peter Nahlstedt President & Chief Executive Officer 3M male
Andy Forreryd Vice President of Sales — male
Helen Olsson Vice President of HR — female
Henrik Johansson Chief Scientist — —
Marianne Olsson Vice President of Finance — female
Tina Dackemark Lawesson Vice President of Marketing & Communications — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Diagnostics & Research